Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis

Subarachnoid Hemorrhage (SAH) is one of the acute neurological conditions that is associated with high mortality and recovery failure rates. In recent years, due to the development of endovascular and classical techniques, the mortality rate after SAH has decreased. Currently, more research is focus...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical medicine 2023-10, Vol.12 (20), p.6638
Hauptverfasser: Kojder, Klaudyna, Jarosz, Konrad, Bosiacki, Mateusz, Andrzejewska, Agata, Zacha, Sławomir, Solek-Pastuszka, Joanna, Jurczak, Anna
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 20
container_start_page 6638
container_title Journal of clinical medicine
container_volume 12
creator Kojder, Klaudyna
Jarosz, Konrad
Bosiacki, Mateusz
Andrzejewska, Agata
Zacha, Sławomir
Solek-Pastuszka, Joanna
Jurczak, Anna
description Subarachnoid Hemorrhage (SAH) is one of the acute neurological conditions that is associated with high mortality and recovery failure rates. In recent years, due to the development of endovascular and classical techniques, the mortality rate after SAH has decreased. Currently, more research is focused on understanding the molecular mechanisms underlying SAH. Methods of treatment are investigated in order to obtain the best treatment result, not only survival. One of the drugs used in stroke, including SAH, is Cerebrolysin. It is a mixture of neuropeptides that has similar properties to neurotrophic factors. Its positive impact on strokes has been analyzed; however, there are no meta-analyses concerning only the subpopulation of patients diagnosed with SAH in the current literature. Therefore, we conducted a meta-analysis of available clinical trials to evaluate the effect of Cerebrolysin on the treatment outcome. The data suggest a positive effect of Cerebrolysin on the mortality of SAH patients. However, further randomized clinical trials with larger groups of patients are needed to draw final conclusions.
doi_str_mv 10.3390/jcm12206638
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10607250</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A772065117</galeid><sourcerecordid>A772065117</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-15399e88c2a5891db21df79ebdb1e801028d0f51e21a3e392d9f6bd732e7a5553</originalsourceid><addsrcrecordid>eNptkl1rHCEUhqW0NCHNVe-L0JtCmdSPdXR6U5alTQIpKU17VxBHz-y6zGiiMwn77-vmq5tQFRR9zquv5yD0lpIjzhvyaW0Hyhipa65eoH1GpKwIV_zlznoPHea8JqUpNWNUvkZ7XKqGSVnvoz8LSNCm2G-yD7iMH2b0EMaMb_y4whdTa5KxqxC9wycwxJRWZgmf8RxfbPIIQ6Et_gnXHm6wCQ5_h9FU82C2evkNetWZPsPh_XyAfn_7-mtxUp2dH58u5meVnUk5VlTwpgGlLDNCNdS1jLpONtC6loIilDDlSCcoMGo48Ia5pqtbJzkDaYQQ_AB9udO9nNoBnC3vT6bXl8kPJm10NF4_PQl-pZfxWlNSE8kEKQof7hVSvJogj3rw2ULfmwBxypopxYUUjPKCvn-GruOUiuNbihUHjMz-UUvTg_ahi-ViuxXVcylLwgSlslBH_6FKdzB4GwN0vuw_Cfh4F2BTzDlB92iSEr0tCL1TEIV-t_svj-xD-vlfex2vSQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2882589204</pqid></control><display><type>article</type><title>Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Kojder, Klaudyna ; Jarosz, Konrad ; Bosiacki, Mateusz ; Andrzejewska, Agata ; Zacha, Sławomir ; Solek-Pastuszka, Joanna ; Jurczak, Anna</creator><creatorcontrib>Kojder, Klaudyna ; Jarosz, Konrad ; Bosiacki, Mateusz ; Andrzejewska, Agata ; Zacha, Sławomir ; Solek-Pastuszka, Joanna ; Jurczak, Anna</creatorcontrib><description>Subarachnoid Hemorrhage (SAH) is one of the acute neurological conditions that is associated with high mortality and recovery failure rates. In recent years, due to the development of endovascular and classical techniques, the mortality rate after SAH has decreased. Currently, more research is focused on understanding the molecular mechanisms underlying SAH. Methods of treatment are investigated in order to obtain the best treatment result, not only survival. One of the drugs used in stroke, including SAH, is Cerebrolysin. It is a mixture of neuropeptides that has similar properties to neurotrophic factors. Its positive impact on strokes has been analyzed; however, there are no meta-analyses concerning only the subpopulation of patients diagnosed with SAH in the current literature. Therefore, we conducted a meta-analysis of available clinical trials to evaluate the effect of Cerebrolysin on the treatment outcome. The data suggest a positive effect of Cerebrolysin on the mortality of SAH patients. However, further randomized clinical trials with larger groups of patients are needed to draw final conclusions.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm12206638</identifier><identifier>PMID: 37892776</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Asymptomatic ; Bias ; Care and treatment ; Clinical medicine ; Clinical trials ; Complications and side effects ; Diagnosis ; Editorials ; Fistula ; Growth factors ; Hemorrhage ; Hormone replacement therapy ; Hypertension ; Intracranial aneurysms ; Meta-analysis ; Mortality ; Prevention ; Risk factors ; Smooth muscle ; Stroke ; Stroke (Disease) ; Subarachnoid hemorrhage ; Systematic Review ; Traumatic brain injury ; Tumor necrosis factor-TNF ; Veins &amp; arteries</subject><ispartof>Journal of clinical medicine, 2023-10, Vol.12 (20), p.6638</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-15399e88c2a5891db21df79ebdb1e801028d0f51e21a3e392d9f6bd732e7a5553</citedby><cites>FETCH-LOGICAL-c477t-15399e88c2a5891db21df79ebdb1e801028d0f51e21a3e392d9f6bd732e7a5553</cites><orcidid>0000-0003-3193-1767 ; 0000-0001-5444-5150 ; 0000-0003-1935-5285 ; 0000-0002-2279-4329</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607250/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607250/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,883,27911,27912,53778,53780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37892776$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kojder, Klaudyna</creatorcontrib><creatorcontrib>Jarosz, Konrad</creatorcontrib><creatorcontrib>Bosiacki, Mateusz</creatorcontrib><creatorcontrib>Andrzejewska, Agata</creatorcontrib><creatorcontrib>Zacha, Sławomir</creatorcontrib><creatorcontrib>Solek-Pastuszka, Joanna</creatorcontrib><creatorcontrib>Jurczak, Anna</creatorcontrib><title>Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis</title><title>Journal of clinical medicine</title><addtitle>J Clin Med</addtitle><description>Subarachnoid Hemorrhage (SAH) is one of the acute neurological conditions that is associated with high mortality and recovery failure rates. In recent years, due to the development of endovascular and classical techniques, the mortality rate after SAH has decreased. Currently, more research is focused on understanding the molecular mechanisms underlying SAH. Methods of treatment are investigated in order to obtain the best treatment result, not only survival. One of the drugs used in stroke, including SAH, is Cerebrolysin. It is a mixture of neuropeptides that has similar properties to neurotrophic factors. Its positive impact on strokes has been analyzed; however, there are no meta-analyses concerning only the subpopulation of patients diagnosed with SAH in the current literature. Therefore, we conducted a meta-analysis of available clinical trials to evaluate the effect of Cerebrolysin on the treatment outcome. The data suggest a positive effect of Cerebrolysin on the mortality of SAH patients. However, further randomized clinical trials with larger groups of patients are needed to draw final conclusions.</description><subject>Asymptomatic</subject><subject>Bias</subject><subject>Care and treatment</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Complications and side effects</subject><subject>Diagnosis</subject><subject>Editorials</subject><subject>Fistula</subject><subject>Growth factors</subject><subject>Hemorrhage</subject><subject>Hormone replacement therapy</subject><subject>Hypertension</subject><subject>Intracranial aneurysms</subject><subject>Meta-analysis</subject><subject>Mortality</subject><subject>Prevention</subject><subject>Risk factors</subject><subject>Smooth muscle</subject><subject>Stroke</subject><subject>Stroke (Disease)</subject><subject>Subarachnoid hemorrhage</subject><subject>Systematic Review</subject><subject>Traumatic brain injury</subject><subject>Tumor necrosis factor-TNF</subject><subject>Veins &amp; arteries</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptkl1rHCEUhqW0NCHNVe-L0JtCmdSPdXR6U5alTQIpKU17VxBHz-y6zGiiMwn77-vmq5tQFRR9zquv5yD0lpIjzhvyaW0Hyhipa65eoH1GpKwIV_zlznoPHea8JqUpNWNUvkZ7XKqGSVnvoz8LSNCm2G-yD7iMH2b0EMaMb_y4whdTa5KxqxC9wycwxJRWZgmf8RxfbPIIQ6Et_gnXHm6wCQ5_h9FU82C2evkNetWZPsPh_XyAfn_7-mtxUp2dH58u5meVnUk5VlTwpgGlLDNCNdS1jLpONtC6loIilDDlSCcoMGo48Ia5pqtbJzkDaYQQ_AB9udO9nNoBnC3vT6bXl8kPJm10NF4_PQl-pZfxWlNSE8kEKQof7hVSvJogj3rw2ULfmwBxypopxYUUjPKCvn-GruOUiuNbihUHjMz-UUvTg_ahi-ViuxXVcylLwgSlslBH_6FKdzB4GwN0vuw_Cfh4F2BTzDlB92iSEr0tCL1TEIV-t_svj-xD-vlfex2vSQ</recordid><startdate>20231020</startdate><enddate>20231020</enddate><creator>Kojder, Klaudyna</creator><creator>Jarosz, Konrad</creator><creator>Bosiacki, Mateusz</creator><creator>Andrzejewska, Agata</creator><creator>Zacha, Sławomir</creator><creator>Solek-Pastuszka, Joanna</creator><creator>Jurczak, Anna</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3193-1767</orcidid><orcidid>https://orcid.org/0000-0001-5444-5150</orcidid><orcidid>https://orcid.org/0000-0003-1935-5285</orcidid><orcidid>https://orcid.org/0000-0002-2279-4329</orcidid></search><sort><creationdate>20231020</creationdate><title>Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis</title><author>Kojder, Klaudyna ; Jarosz, Konrad ; Bosiacki, Mateusz ; Andrzejewska, Agata ; Zacha, Sławomir ; Solek-Pastuszka, Joanna ; Jurczak, Anna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-15399e88c2a5891db21df79ebdb1e801028d0f51e21a3e392d9f6bd732e7a5553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Asymptomatic</topic><topic>Bias</topic><topic>Care and treatment</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Complications and side effects</topic><topic>Diagnosis</topic><topic>Editorials</topic><topic>Fistula</topic><topic>Growth factors</topic><topic>Hemorrhage</topic><topic>Hormone replacement therapy</topic><topic>Hypertension</topic><topic>Intracranial aneurysms</topic><topic>Meta-analysis</topic><topic>Mortality</topic><topic>Prevention</topic><topic>Risk factors</topic><topic>Smooth muscle</topic><topic>Stroke</topic><topic>Stroke (Disease)</topic><topic>Subarachnoid hemorrhage</topic><topic>Systematic Review</topic><topic>Traumatic brain injury</topic><topic>Tumor necrosis factor-TNF</topic><topic>Veins &amp; arteries</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kojder, Klaudyna</creatorcontrib><creatorcontrib>Jarosz, Konrad</creatorcontrib><creatorcontrib>Bosiacki, Mateusz</creatorcontrib><creatorcontrib>Andrzejewska, Agata</creatorcontrib><creatorcontrib>Zacha, Sławomir</creatorcontrib><creatorcontrib>Solek-Pastuszka, Joanna</creatorcontrib><creatorcontrib>Jurczak, Anna</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kojder, Klaudyna</au><au>Jarosz, Konrad</au><au>Bosiacki, Mateusz</au><au>Andrzejewska, Agata</au><au>Zacha, Sławomir</au><au>Solek-Pastuszka, Joanna</au><au>Jurczak, Anna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis</atitle><jtitle>Journal of clinical medicine</jtitle><addtitle>J Clin Med</addtitle><date>2023-10-20</date><risdate>2023</risdate><volume>12</volume><issue>20</issue><spage>6638</spage><pages>6638-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>Subarachnoid Hemorrhage (SAH) is one of the acute neurological conditions that is associated with high mortality and recovery failure rates. In recent years, due to the development of endovascular and classical techniques, the mortality rate after SAH has decreased. Currently, more research is focused on understanding the molecular mechanisms underlying SAH. Methods of treatment are investigated in order to obtain the best treatment result, not only survival. One of the drugs used in stroke, including SAH, is Cerebrolysin. It is a mixture of neuropeptides that has similar properties to neurotrophic factors. Its positive impact on strokes has been analyzed; however, there are no meta-analyses concerning only the subpopulation of patients diagnosed with SAH in the current literature. Therefore, we conducted a meta-analysis of available clinical trials to evaluate the effect of Cerebrolysin on the treatment outcome. The data suggest a positive effect of Cerebrolysin on the mortality of SAH patients. However, further randomized clinical trials with larger groups of patients are needed to draw final conclusions.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>37892776</pmid><doi>10.3390/jcm12206638</doi><orcidid>https://orcid.org/0000-0003-3193-1767</orcidid><orcidid>https://orcid.org/0000-0001-5444-5150</orcidid><orcidid>https://orcid.org/0000-0003-1935-5285</orcidid><orcidid>https://orcid.org/0000-0002-2279-4329</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2077-0383
ispartof Journal of clinical medicine, 2023-10, Vol.12 (20), p.6638
issn 2077-0383
2077-0383
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10607250
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central
subjects Asymptomatic
Bias
Care and treatment
Clinical medicine
Clinical trials
Complications and side effects
Diagnosis
Editorials
Fistula
Growth factors
Hemorrhage
Hormone replacement therapy
Hypertension
Intracranial aneurysms
Meta-analysis
Mortality
Prevention
Risk factors
Smooth muscle
Stroke
Stroke (Disease)
Subarachnoid hemorrhage
Systematic Review
Traumatic brain injury
Tumor necrosis factor-TNF
Veins & arteries
title Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T15%3A59%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cerebrolysin%20in%20Patients%20with%20Subarachnoid%20Hemorrhage:%20A%20Systematic%20Review%20and%20Meta-Analysis&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Kojder,%20Klaudyna&rft.date=2023-10-20&rft.volume=12&rft.issue=20&rft.spage=6638&rft.pages=6638-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm12206638&rft_dat=%3Cgale_pubme%3EA772065117%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2882589204&rft_id=info:pmid/37892776&rft_galeid=A772065117&rfr_iscdi=true